175 related articles for article (PubMed ID: 32415419)
1. Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?
Pahan P; Pahan K
J Neuroimmune Pharmacol; 2020 Jun; 15(2):174-180. PubMed ID: 32415419
[TBL] [Abstract][Full Text] [Related]
2. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
[TBL] [Abstract][Full Text] [Related]
3. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.
Lei ZN; Wu ZX; Dong S; Yang DH; Zhang L; Ke Z; Zou C; Chen ZS
Pharmacol Ther; 2020 Dec; 216():107672. PubMed ID: 32910933
[TBL] [Abstract][Full Text] [Related]
4. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
Naghipour S; Ghodousi M; Rahsepar S; Elyasi S
Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1119-1133. PubMed ID: 32631083
[TBL] [Abstract][Full Text] [Related]
5. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
Rodrigo C; Fernando SD; Rajapakse S
Clin Microbiol Infect; 2020 Aug; 26(8):979-987. PubMed ID: 32470568
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine and COVID-19.
Sinha N; Balayla G
Postgrad Med J; 2020 Sep; 96(1139):550-555. PubMed ID: 32295814
[TBL] [Abstract][Full Text] [Related]
7. Risk of using hydroxychloroquine as a treatment of COVID-19.
Alanagreh L; Alzoughool F; Atoum M
Int J Risk Saf Med; 2020; 31(3):111-116. PubMed ID: 32474476
[TBL] [Abstract][Full Text] [Related]
8. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
Fatima U; Rizvi SSA; Fatima S; Hassan MI
J Interferon Cytokine Res; 2020 Oct; 40(10):469-471. PubMed ID: 32881593
[TBL] [Abstract][Full Text] [Related]
9. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Nina PB; Dash AP
Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
[TBL] [Abstract][Full Text] [Related]
11. [Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
Vollaard A; Gieling EM; van der Linden PD; Sinha B; de Boer MGJ
Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749808
[TBL] [Abstract][Full Text] [Related]
12. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
13. [Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine].
Tomcsányi J; Tomcsányi K
Orv Hetil; 2020 Apr; 161(17):689-691. PubMed ID: 32324363
[TBL] [Abstract][Full Text] [Related]
14. The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
Martinez GP; Zabaleta ME; Di Giulio C; Charris JE; Mijares MR
Curr Pharm Des; 2020; 26(35):4467-4485. PubMed ID: 32634079
[TBL] [Abstract][Full Text] [Related]
15. Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies.
Marouf BH; Dizaye K
Drug Discov Ther; 2020; 14(3):109-116. PubMed ID: 32669519
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.
Bansal P; Goyal A; Cusick A; Lahan S; Dhaliwal HS; Bhyan P; Bhattad PB; Aslam F; Ranka S; Dalia T; Chhabra L; Sanghavi D; Sonani B; Davis JM
Ann Med; 2021 Dec; 53(1):117-134. PubMed ID: 33095083
[TBL] [Abstract][Full Text] [Related]
17. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
[TBL] [Abstract][Full Text] [Related]
18. Update on antimalarials and systemic lupus erythematosus.
Ruiz-Irastorza G; Martín-Iglesias D; Soto-Peleteiro A
Curr Opin Rheumatol; 2020 Nov; 32(6):572-582. PubMed ID: 32890029
[TBL] [Abstract][Full Text] [Related]
19. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
Fantini J; Di Scala C; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 May; 55(5):105960. PubMed ID: 32251731
[TBL] [Abstract][Full Text] [Related]
20. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.
Kara E; Demirkan K; Unal S
Int J Antimicrob Agents; 2020 Sep; 56(3):106123. PubMed ID: 32738307
[No Abstract] [Full Text] [Related]
[Next] [New Search]
